miR-216b Targets FGFR1 and Confers Sensitivity to Radiotherapy in Pancreatic Ductal Adenocarcinoma Patients Without EGFR or KRAS Mutation.

EGELİ Ü., Tezcan G., ÇEÇENER G., TUNCA B., Sevinc E. D., KAYA E., ...Daha Fazla

Pancreas, cilt.45, sa.9, ss.1294-302, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 45 Sayı: 9
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1097/mpa.0000000000000640
  • Dergi Adı: Pancreas
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1294-302
  • Anahtar Kelimeler: pancreatic ductal adenocarcinoma, EGFR, KRAS, miR-216b, FGFR1, radiotherapy resistance, COLORECTAL-CANCER, GEMCITABINE, PROGRESSION, METASTASIS, INHIBITION, MICRORNAS, PROGNOSIS, CARCINOMA, INVASION, IMPACT
  • Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Objectives: The success of gemcitabine plus radiotherapy is dependent on the mutation status of pancreatic ductal adenocarcinoma (PDAC) tumors in the EGFR and KRAS genes; however, radiotherapy resistance may also be modulated epigenetically by microRNA (miRNA) regulation. In this study, we examined the potential effect of miRNAs on the resistance to radiotherapy in cases without EGFR or KRAS mutation.